GSK publishes Annual Report 2025

Summary by AI ^BETAClose X

GSK plc has published its Annual Report for the year ended 31 December 2025, making it available on its website and submitting it to the FCA's National Storage Mechanism. Shareholders who have elected for paper communications will receive a hard copy of the report and the Notice of Annual General Meeting 2026 around 25 March 2026, with the AGM Notice also being made available to other shareholders on the same date. This announcement serves to comply with FCA disclosure requirements, and the full report contains all information required for media communication.

Disclaimer*

GSK PLC

05 March 2026

GSK plc

(the 'Company')

Publication of Annual Report 2025

The Company has today published on its website https://annualreport.gsk.com its Annual Report for the year ended 31 December 2025 ('Annual Report 2025').

In compliance with Listing Rule 6.4.1R of the UK Financial Conduct Authority ('FCA'), the Annual Report 2025 has been submitted to the FCA's National Storage Mechanism ('NSM') and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

A hard copy version of the Annual Report 2025 and the Notice of Annual General Meeting 2026 ('AGM Notice') will be sent to those shareholders who have elected to receive paper communications on or around 25 March 2026. The AGM Notice will be made available to shareholders who have not elected to receive paper communications on the same date.

This announcement is not a substitute for reading the Annual Report 2025 in full.

Additional Information

For the purposes of complying with the FCA's Disclosure Guidance and Transparency Rules ('DTRs') and the requirements imposed on issuers through the DTRs, information required to be communicated with the media in unedited full text was included in the Annual Report 2025. The Annual Report 2025 was submitted to the NSM and will shortly be available for inspection. It is also available on the Company's website as noted above.

This announcement is made in accordance with DTR 6.3.5R(1A).

V A Whyte

Company Secretary

5 March 2026

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END